Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023990 | 0.78 | KCNA3 (0.37) | MAOBMAOAFTOKCNA3SLC6A4 | |
| SCHEMBL24897489 | 0.76 | MAOB (0.33) | MAOBMAOAFTO | |
| SCHEMBL2607564 | 0.76 | CA2 (0.41) | MAOBMAOAFTOKCNA3CA2 | |
| SCHEMBL2607820 | 0.74 | MAOB (0.40) | MAOBMAOAFTOCA2PTPN1 | |
| SCHEMBL20227028 | 0.74 | MAOB (0.35) | MAOBMAOACA2CYP2C19CYP3A4 | |
| SCHEMBL29477140 | 0.73 | MAOA (0.38) | MAOBMAOAFTOKCNA3CA2 | |
| SCHEMBL23615738 | 0.72 | MAOB (0.41) | MAOBMAOACA2KCNA5PTPN1 | |
| SCHEMBL4012908 | 0.71 | CA2 (0.42) | MAOBMAOACA2PTPN1 | |
| SCHEMBL26247195 | 0.71 | CA2 (0.40) | MAOBMAOAFTOCA2SLC6A4 | |
| SCHEMBL6090241 | 0.69 | MTNR1A (0.37) | MAOBMAOAFTOKCNA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | MAOB 2656/4885MAOA 2724/4885FTO 3846/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | MAOB 1001/4885MAOA 1371/4885FTO 4500/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | MAOB 110/4885MAOA 251/4885FTO 4321/4885 |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | MAOB 2656/4885MAOA 2724/4885FTO 3846/4885 |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | MAOB 2656/4885MAOA 2724/4885FTO 3846/4885 |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | MAOB 2656/4885MAOA 2724/4885FTO 3846/4885 |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | MAOB 2656/4885MAOA 2724/4885FTO 3846/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | MAOB 3047/4885MAOA 3211/4885FTO 4273/4885 |
| US-11708320-B2 | Environmentally-friendly hydroazidation of olefins | HAO2, AHR, HMOX1 | MAOB 361/4885MAOA 309/4885FTO 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.